Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Johnson and Johnson
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tivozanib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Tivozanib: Patents, clinical trial progress, indications

Tivozanib is an investigational drug.

There have been 31 clinical trials for Tivozanib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Colorectal Neoplasms. The leading clinical trial sponsors are AVEO Pharmaceuticals, Inc., National Comprehensive Cancer Network, and Massachusetts General Hospital.

There are fifteen US patents protecting this investigational drug and one hundred and thirty-nine international patents.

Recent Clinical Trials for Tivozanib
TitleSponsorPhase
A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular CarcinomaAstraZenecaPhase 1/Phase 2
A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular CarcinomaAVEO Pharmaceuticals, Inc.Phase 1/Phase 2
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCBristol-Myers SquibbPhase 1/Phase 2

See all Tivozanib clinical trials

Clinical Trial Summary for Tivozanib

Top disease conditions for Tivozanib
Top clinical trial sponsors for Tivozanib

See all Tivozanib clinical trials

US Patents for Tivozanib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tivozanib   Start Trial Quinoline derivatives and quinazoline derivatives having azolyl group Kirin Beer Kabushiki Kaisha (Tokyo-to, JP)   Start Trial
Tivozanib   Start Trial N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxaz- olyl)urea salt in crystalline form Kirin Beer Kabushiki Kaisha (Tokyo-To, JP)   Start Trial
Tivozanib   Start Trial Quinoline derivatives and quinazoline derivatives having azolyl group Kirin Beer Kabushiki Kaisha (Tokyo-To, KR)   Start Trial
Tivozanib   Start Trial Tivozanib response prediction AVEO Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tivozanib   Start Trial Tivozanib response prediction AVEO Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tivozanib   Start Trial Tivozanib and temsirolimus in combination AVEO Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tivozanib   Start Trial Fully human anti-VEGF antibodies and methods of using Schering Corporation (Kenilworth, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tivozanib

Drugname Country Document Number Estimated Expiration Related US Patent
Tivozanib Austria 314361 2021-04-27   Start Trial
Tivozanib Austria 396988 2021-04-27   Start Trial
Tivozanib Australia 2002255284 2021-04-27   Start Trial
Tivozanib Brazil 0209216 2021-04-27   Start Trial
Tivozanib Brazil PI0209216 2021-04-27   Start Trial
Tivozanib Canada 2445333 2021-04-27   Start Trial
Tivozanib China 1273466 2021-04-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Harvard Business School
McKinsey
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.